

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 April 2007 (05.04.2007)

PCT

(10) International Publication Number
WO 2007/036715 A3

(51) International Patent Classification:

C07D 235/26 (2006.01) A61K 31/4184 (2006.01)
C07D 405/12 (2006.01) A61P 25/00 (2006.01)

(21) International Application Number:

PCT/GB2006/003590

(22) International Filing Date:

27 September 2006 (27.09.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

0519950.0 30 September 2005 (30.09.2005) GB
0602040.8 1 February 2006 (01.02.2006) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUDZIK, Brian** [US/US]; GlaxoSmithKline, 1250 South Collegeville Road, P.O. Box 5089, Collegeville, Pennsylvania 19426 (US). **COOPER, David, Gwyn** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **FORBES, Ian, Thomson** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **GARZYA, Vincenzo** [IT/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **JIN, Jian** [US/US]; GlaxoSmithKline, 1250 South Collegeville Road, P.O. Box 5089, Collegeville, Pennsylvania 19426 (US). **SHI, Dongchuan** [CN/US]; GlaxoSmithKline, 1250 South Collegeville Road, P.O. Box 5089, Collegeville, Pennsylvania 19426 (US). **SMITH, Paul, William** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB). **WALKER,**

Graham [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow Essex CM19 5AW (GB).

(74) Agent: **KONDO, Rie**; GlaxoSmithKline, Corporate Intellectual Property (cn925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

(54) Title: COMPOUNDS WHICH HAVE ACTIVITY AT M₁ RECEPTOR AND THEIR USES IN MEDICINE

(I)

(57) Abstract: Compounds which have activity at M₁ receptor and their uses in medicine Compounds of formula (I) and salts and solvates are provided: wherein R⁴ is fluoro, R⁵ is selected from hydrogen, halogen, cyano, C₁₋₆alkyl, C₁₋₆alkyl substituted with one or more fluorine atoms, C₁₋₆alkoxy, and C₁₋₆alkoxy substituted with one or more fluorine atoms; and R⁶ is selected from halogen, cyano, C₁₋₆alkyl, C₁₋₆alkyl substituted with one or more fluorine atoms, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl substituted with one or more fluorine atoms, C₁₋₆alkoxy and C₁₋₆alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C₁₋₆alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.

WO 2007/036715 A3



(88) Date of publication of the international search report:

18 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.